stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) EV/FCF
As of 5 November 2026, Cytokinetics, Incorporated (CYTK) trades at a EV/FCF of −12.7×. Over the past ten years it has ranged from −631× (March 2021) to 72.8× (January 2016); the current reading is higher than 39% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −14.8× | — |
| FY2024 | −12.1× | — |
| FY2023 | −19.5× | — |
| FY2022 | −12.3× | — |
| FY2021 | −16.7× | — |
| FY2020 | −481× | — |
| FY2019 | −5.6× | — |
| FY2018 | −1.8× | — |
| FY2017 | −2.0× | — |
| FY2016 | 10.4× | (85.44%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −15.1× | — |
| Jun 2026 | −19.3× | — |
| Mar 2026 | −15.4× | — |
| Dec 2025 | −14.8× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −100× |
| TWST Twist Bioscience Corporation compare | −77.9× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −64.5× |
| SYRE Spyre Therapeutics, Inc. compare | −30.3× |
| CYTK Cytokinetics, Incorporated | −12.7× |
| KRYS Krystal Biotech, Inc. compare | 25.7× |
| CORT Corcept Therapeutics Incorporated compare | 37.7× |
| PTGX Protagonist Therapeutics, Inc. compare | 62.4× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement